Jared Kesselheim
Co-Founder & Managing Partner @ Transformation Capital
Boston, United States
Jared Kesselheim is a Series B investor at Transformation Capital in Boston focused on Health Care and Medical. Jared Kesselheim, MD, brings to Transformation Capital more than fifteen years of investing and clinical experience and has a demonstrated history of identifying compelling companies and helping them realize continued innovation, growth and strong exits. Jared co-founded Transformation Capital’s predecessor management company in 2016 and serves onthe boards of six Fund I portfolio companies: Vera Whole Health, Scientist.com, Aktana, Protenus, Groups, and Panalgo.Previously, Jared was at Bain Capital Ventures, where he was a leader of their digital health practice, focusing on investments in digital health as part of an $850 million multi-sector fund. He became a Partner of Bain Capital Ventures in January 2014, having previously served as an Associate and Principal after joining that firm in July 2008.During his time at Bain Capital Ventures, Jared was involved in multiple high growth investments including: Apixio (Board Director), Remedy Partners (Board Observer; acquired by New Mountain Capital in 2019), ABILITY Network (Board Director after being Board Observer; acquired by Summit Partners in 2014 and acquired by Inovalon in 2018), MedHOK (Board Observer; acquired by Hearst in 2016), National Cardiovascular Partners (Board Observer; acquired by Fresenius in 2014), and Liazon (Board Observer, acquired by Towers Watson in 2014).Prior to his investing career, Jared completed a residency in Internal Medicine at Massachusetts General Hospital. As a resident physician, he oversaw a primary care panel of 300 patients and directed care teams within the hospital’s general medical wards and the medical intensive care unit.Jared graduated from Harvard College summa cum laude and Phi Beta Kappa with a degree in Biochemical Sciences, where he also co-wrote the 1997 Hasty Pudding Theatricals musical “Me and My Galaxy." He also received an MD from Harvard Medical School and an MBA from Harvard Business School where he was a Baker Scholar and an enthusiastic bench warmer for the HBS Club Hockey team. At home in Newton, Massachusetts, Jared and his wife Dara continue to work in vain on developing strategies for preventing their three young boys from treating all furniture as a form of playground equipment.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Jared Kesselheim invests in
Stages Jared Kesselheim invests in
Countries Jared Kesselheim invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 10 (50%)
- Medical 4 (20%)
- Software 3 (15%)
- Analytics 2 (10%)
- Biotechnology 2 (10%)
Stage
- Series B 4 (20%)
- Series C 4 (20%)
- Series A 2 (10%)
- Series D 2 (10%)
- Private Equity 2 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Qualified Health is a reliable partner for safely utilizing generative AI in medicine. Qualified Health's infrastructure solution offers safeguards for ongoing algorithm performance monitoring, active AI governance, and developing agents tailored to the healthcare industry. Qualified Health are revolutionizing healthcare in America with tophealth system partners. | $125M / Series B / Mar 25, 2026 | ||
| Capital Rx is a health technology company that engages in managing pharmacy benefit plans. The company is redefining the way prescriptions are priced and administered in the U.S. Through its Clearinghouse Model, it unlocks the pharmacy supply chain and reduces prescription costs for employer groups. By establishing a competitive marketplace fordrug pricing, Capital Rx focuses its resources on deploying actionable strategies that improve plan performance and patient outcomes. | $252M / Series F / Sep 23, 2025 | ||
| World Class Health is a Hospitals and Health Care company. | $10M / Venture - Series Unknown / Apr 24, 2025 | ||
| Capital Rx is a health technology company that engages in managing pharmacy benefit plans. The company is redefining the way prescriptions are priced and administered in the U.S. Through its Clearinghouse Model, it unlocks the pharmacy supply chain and reduces prescription costs for employer groups. By establishing a competitive marketplace fordrug pricing, Capital Rx focuses its resources on deploying actionable strategies that improve plan performance and patient outcomes. | Oct 11, 2023 | ||
| Capital Rx is a health technology company that engages in managing pharmacy benefit plans. The company is redefining the way prescriptions are priced and administered in the U.S. Through its Clearinghouse Model, it unlocks the pharmacy supply chain and reduces prescription costs for employer groups. By establishing a competitive marketplace fordrug pricing, Capital Rx focuses its resources on deploying actionable strategies that improve plan performance and patient outcomes. | $50M / Series D / Oct 11, 2023 | ||
| Capital Rx is a health technology company that engages in managing pharmacy benefit plans. The company is redefining the way prescriptions are priced and administered in the U.S. Through its Clearinghouse Model, it unlocks the pharmacy supply chain and reduces prescription costs for employer groups. By establishing a competitive marketplace fordrug pricing, Capital Rx focuses its resources on deploying actionable strategies that improve plan performance and patient outcomes. | $50M / Series D / Oct 11, 2023 | ||
| Capital Rx is a health technology company that engages in managing pharmacy benefit plans. The company is redefining the way prescriptions are priced and administered in the U.S. Through its Clearinghouse Model, it unlocks the pharmacy supply chain and reduces prescription costs for employer groups. By establishing a competitive marketplace fordrug pricing, Capital Rx focuses its resources on deploying actionable strategies that improve plan performance and patient outcomes. | $106M / Series C / Jun 13, 2022 | ||
| Capital Rx is a health technology company that engages in managing pharmacy benefit plans. The company is redefining the way prescriptions are priced and administered in the U.S. Through its Clearinghouse Model, it unlocks the pharmacy supply chain and reduces prescription costs for employer groups. By establishing a competitive marketplace fordrug pricing, Capital Rx focuses its resources on deploying actionable strategies that improve plan performance and patient outcomes. | $106M / Series C / Jun 13, 2022 | ||
| H1 is an AI-powered platform that helps identify and engage the right doctors for critical workflows across pharma, health plan, health system, and technology companies. At the core of the platform is H1’s Doctor Graph—a structured representation of physician identity, expertise, relationships, and behavioral signals, creating a powerful networkeffect as it is continuously enriched by participants across the healthcare ecosystem. Built on one of the world’s largest and most comprehensive global datasets of healthcare professionals, H1 combines deep healthcare data with agentic AI workflows to power critical workflows across drug development, medical and commercial engagement, care navigation, and provider data and network intelligence. Founded in 2017, the company is based in New York, United States. | $23M / Series C / Jun 09, 2022 | ||
| Jeenie is a Human + AI multilingual platform that delivers instant, culturally-intelligent communication — anytime and anywhere. Built for today’s global world, Jeenie connects professionals to a remote, global network of human interpreters in under 10 seconds across 300+languages and offers critical language support for healthcare providers whilealso supporting industries like legal, education, and immigration. Jeenie makes it easy for clients to communicate seamlessly with the help of world-class interpreters, and Jeenie's focus on quality is reflected in a 4.9-star client rating. | $9.3M / Series A / Mar 31, 2022 | ||
| See all 20 investments → | |||
Co-Investors
About Transformation Capital
Transformation Capital is the successor management company to Leerink Transformation Partners LLC (“LTP”).11 LTP was founded in 2016 by Todd Cozzens and Jared Kesselheim, MD together with SVB Leerink Capital LLC (formerly Leerink Capital Partners LLC) (“Leerink Capital”), an affiliate of SVB Leerink LLC (“Leerink”), a leading healthcare investmentbank. Leerink Capital provided seed capital to Fund I (approximately 3% of capital commitments) and operational support. In January 2019, SVB Financial Group (“SVB”), the holding company of Silicon Valley Bank, a U.S.-based high-tech commercial bank, acquired the Leerink businesses including Leerink Capital. Todd Cozzens, Jared Kesselheim, MD, and SVB expect to agree to a mutually beneficial ongoing relationship in which Transformation Capital (as an independent management company owned by Todd Cozzens, Jared Kesselheim, MD, and Michael Dixon and not affiliated with SVB or Leerink Capital) shall manage Fund II and whereby Transformation Capital shall manage Fund I’s investment portfolio pursuant to a sub-advisory agreement with SVB (or an affiliate). Transformation Capital has the same operational leader, Kevin Brown, formerly CFO of Leerink Capital, and Transformation Capital expects to continue to derive benefits from its ongoing relationship with Leerink and SVB.
Transformation Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jared Kesselheim
Co-Founder & Managing Partner
|
|||
Jenna Ciotti
Vice President
|
|||
Julie Murchinson
Partner
|
|||
Michael Dixon
Managing Partner
|
|||
Todd Cozzens
Co-Founder & Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jared Kesselheim invest in?
Jared Kesselheim invests primarily in Health Care, Medical and Software startups, most often at Series B and Series C stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jared Kesselheim?
Public channels for Jared Kesselheim include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jared Kesselheim last invest?
The most recent investment recorded for Jared Kesselheim closed in Mar 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
